Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
21.10.Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
20.10.Rapport's epilepsy drug finds surprising success in bipolar trial
20.10.Most new drugs are still too costly at launch, ICER says
20.10.Hype vs. reality: What pharma's hottest R&D bets have actually proved
19.10.Disc's once-spurned rare disease drug to get a second chance at approval
19.10.Merck KGaA bets on RNAi with $1.3B Silence buyout
19.10.Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
19.10.From strategy to scale: How Saudi Arabia is building a biotech ecosystem
19.10.Extractables in single-use systems used in ADC manufacturing
19.10.How early should you engage a CDMO?
16.10.Iambic CEO on taking an AI drug company public
16.10.This week in charts: Moderna's massive stock run
16.10.Next-gen RNAi drugmaker City prices $200M IPO
16.10.Biogen-backed Estuary nabs $93M for liver disease gene therapy
15.10.Belgian startup revives Galapagos CAR-T research
15.10.FDA 'reset' continues with new plan for reviewing rare disease drugs
15.10.Iambic, an AI drug discovery specialist, banks $150M in an IPO
14.10.Experimental Arrowhead RNAi drug hints at Alzheimer's benefit
14.10.J&J earnings set 'negative tone'; Shkreli vs. the FTC
14.10.Verastem cancer drug shows early promise in small study
13.10.Decreasing process variability in fluid management systems
13.10.Another Paragon Labs spinout goes public through reverse merger
13.10.BioNTech mRNA cancer immunotherapy misses first objective in key study
13.10.Roche extends China deal streak with $1B pact for RNAi obesity drug
12.10.First Tracks climbs on 'impressive' celiac study data